Navigation Links
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors

vely kills cisplatin-resistant cells when used as monotherapy, and restores cisplatin sensitivity. Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers. However, development of cisplatin resistance is a common event and the ability of INGN 241 to kill these resistant tumors and restore cisplatin efficacy has important clinical implications. Previous INGN 241 preclinical studies have indicated similar synergies with other chemotherapies and with radiation treatment.

Dr. Chada added, "These preclinical data demonstrate that INGN 241 can restore sensitivity to cisplatin, a widely used chemotherapy drug that frequently gives rise to resistance. Our findings support applications of INGN 241 in combination with standard chemotherapy and radiation regimens and we are planning future clinical trials based on these results."

About INGN 241

INGN 241 is being tested in a Phase 2 clinical trial for patients suffering from advanced melanoma and in a Phase 3 clinical trial in combination with radiation therapy in solid tumors. The mda-7 gene is the active component of INGN 241 and was discovered in the laboratory of Dr. Paul B. Fisher, professor of clinical pathology at Columbia University. Introgen holds an exclusive worldwide sublicense to the Columbia University rights for all gene therapy applications from GlaxoSmithKline.

About Introgen

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale
'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... May 1, 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development ... its annual report on Form 20-F for the ... States Securities and Exchange Commission (the "SEC"). The ...
... 2012 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... live webcast on Tuesday, May 8, 2012 at 4:30 p.m. ... a business and financial update and review first quarter 2012 ... be accessed from the Investors section of the Jazz Pharmaceuticals ...
Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... , Shaking hands with a robotic arm could be a ... arms again. Researchers writing in BioMed Central,s open access ... of the ,Braccio di Ferro, (Iron arm) robot in 10 ... worked with a team of researchers from the Italian Institute ...
... (March 15, 2010) New research findings published in the ... of Surgeons indicate that some breast cancers continue to ... through mammographic screening. Patients who presented with palpable tumors ... examination had larger tumors and were at a more ...
... ... symptoms.* , ... Clemente, CA (Vocus) March 15, 2010 -- Metagenics, Inc. announced today that ... to address the needs of menopausal women. The key active ingredient in Estrovera is ...
... National Alliance of Wound Care® (NAWC®), in cooperation ... Patient Safety and the New Jersey Department of Health and ... to expand the number of wound care certified professionals through ... This new initiative was borne of the idea of making ...
... March 15 (OTC Bulletin Board: WNDM) Wound ... products, announced today that its subsidiary Wound Care Innovations ... Conference in Los Angeles March 18-20 ... researchers, scientists, and limb salvage experts from all 50 ...
... Taking antidepressant plus naltrexone improves odds of not drinking, ... Combined treatment with the antidepressant Zoloft (sertraline) and the ... both major depression and alcohol dependence will be able ... study of 170 patients found that 54 percent of ...
Cached Medicine News:Health News:Palpable breast cancers are more common in women not undergoing annual mammography 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 3Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 2Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 3Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 4Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 2Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 3Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 4Health News:New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals 5Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 2Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 3Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 4Health News:Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference 5
... Anatomic Knee system was designed to ... all articulating surfaces, to minimize contact ... achieve a well balanced knee with ... The MJS Knee system allows maximum ...
... of digital mobile imaging just got ... software and instrumentation. Now using,your C-arm ... Easily Add Visualization and Navigation ... Accelerate Intraoperative Decision Making, Provide ...
... GE's surgical navigation for ... system to integrate C-arm ... technology. It features automatic ... image to the patient's ...
... on over 20 years of CT engineering ... is at the forefront of the revolution ... acquire volumetric data at high speed with ... based on extensive clinical experience and close ...
Medicine Products: